Magnesium for eclampsia

Saunders, Nigel; Hammersley, Beth

doi:10.1016/s0140-6736(95)91614-8

Cited by 13 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mg 2+ has been shown to have anticonvulsive properties in eclampsia (Saunders and Hammersley 1995). Our Þndings are therefore in line with the assumption of an NMDA-antagonistic and a GABA agonistic e¦cacy of Mg 2+ , and hence Mg 2+ may be beneÞcial in treating some forms of seizures.…”

Section: Discussionsupporting

confidence: 87%

“…MgSO 4 was given in a glucose solution rather than an NaCl solution to minimize e¤ects of osmolarity. The dosage chosen is in the lower range of that used in the treatment of eclampsia (Saunders and Hammersley 1995). Placebo and MgSO 4 solutions were administered through an IV catheter connected to plastic tubing that ran through a soundproof lock into the adjacent room.…”

Section: Protocolmentioning

confidence: 99%

See 1 more Smart Citation

Mg 2+ reduces ACTH secretion and enhances spindle power without changing delta power during sleep in men - possible therapeutic implications

Murck¹,

Steiger²

1998

Psychopharmacology

View full text Add to dashboard Cite

Disturbances of Mg2+ metabolism have been reported in association with affective disorders, seizures in eclampsia, and alcohol withdrawal. Mg2+ has been reported to have N-methyl-D-aspartate (NMDA)-antagonistic and gamma-aminobutyric acid (GABA)-agonistic properties and modulation of GABA(A)- and NMDA-dependent systems is involved in pharmacological treatment of affective disorders and seizures. We studied the effect of Mg2+ on sleep electroencephalogram (EEG) and nocturnal hormonal secretion in men. Ten normal controls were given MgSO4 (3 g MgSO4 between 2030 hours and 2100 hours, followed by 0.5 g MgSO4 per hour until 0700 hours) or placebo i.v. according to a randomized schedule. The sleep EEG was recorded from 2300 hours to 0700 hours. Blood samples were taken from 2000 hours to 0700 hours for analysis of plasma corticotropin (ACTH), cortisol, growth hormone, prolactin and melatonin. The sleep-EEG power within the spindle frequency range (11.0-12.9 Hz) showed a significant increase in the third sleep cycle, but delta power was unchanged throughout the night. ACTH concentration was suppressed between 2200 hours and 0700 hours. No changes in cortisol, growth hormone prolactin or melatonin release were found. The findings are consistent with the assumption that Mg2+ has GABA(A)-agonistic or NMDA-antagonistic effects on sleep and nocturnal hormonal secretion and hence may be useful in controlling depressive symptoms and seizures.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Protocolmentioning

confidence: 99%

Mg 2+ reduces ACTH secretion and enhances spindle power without changing delta power during sleep in men - possible therapeutic implications

Murck¹,

Steiger²

1998

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Recently new evidence has led to several editorials 5,6 and a commentary 7 encouraging obstetricians to use magnesium sulphate in eclampsia and pre‐eclampsia. However, a systematic review of the literature on the effectiveness of magnesium sulphate has not been reported in a peer reviewed journal.…”

Section: Introductionmentioning

confidence: 99%

Magnesium sulphate in the treatment of eclampsia and pre‐eclampsia: an overview of the evidence from randomised trials

Chien

Khan

Arnott

1996

BJOG

View full text Add to dashboard Cite

Objective To evaluate the effectiveness of magnesium sulphate in the treatment of eclampsia and pre‐eclampsia by a systematic quantitative overview of controlled clinical trials. Design Online searching of the MEDLINE database between 1966 and 1995, and scanning of the bibliography of known primary studies and review articles on the use of magnesium sulphate in eclampsia and pre‐eclampsia. Study selection, study quality assessment and data extraction were performed independently by two reviewers under masked conditions. Where possible outcome data from trials were pooled and summarised using the Mantel‐Haenszel method. Participants One thousand seven hundred and forty‐three women with eclampsia and 2390 with pre‐eclampsia included in nine randomised trials that evaluated the effects of magnesium sulphate. Main outcome measures Seizure activity and maternal death. Results In eclampsia, recurrence of seizures was less common with magnesium sulphate therapy compared with phenytoin (odds ratio [OR] 0.27, 95% CI 0.17.0.45, P= 0.00) and diazepam (OR 0–41, 95% CI 0.30–0.57, P= 0.00). As indicated by the point estimate, there was a trend towards a reduction in maternal mortality with magnesium sulphate in eclampsia (OR 0.51,95% CI 0.24–1.07, P= 0.10versus phenytoin; OR 0.78, 95% CI 0.41–1.45, P= 0.52versus diazepam). When used for seizure prophylaxis in pre‐eclampsia, magnesium sulphate was found to be more effective than phenytoin (OR 0.15, 95% CI 0.03–0.72, P= 0.01). Conclusion Magnesium sulphate is a superior drug in preventing the recurrence of seizures in eclampsia and in seizure prophylaxis in pre‐eclampsia.

show abstract

“…The drug remains the most useful agent for the prevention of seizures associated with severe preeclampsia (Saunders and Hammersley 1995 ). Magnesium sulfate is a neuromuscular blocker and appears to prevent the end-organ consequences of prolonged hypoxemia that may occur with concomitant seizure activity.…”

Section: Magnesium Sulfatementioning

confidence: 99%

Cardiac Drug Therapy

Khan

2015

Contemporary Cardiology

View full text Add to dashboard Cite

Magnesium for eclampsia

Cited by 13 publications

References 12 publications

Mg 2+ reduces ACTH secretion and enhances spindle power without changing delta power during sleep in men - possible therapeutic implications

Mg 2+ reduces ACTH secretion and enhances spindle power without changing delta power during sleep in men - possible therapeutic implications

Magnesium sulphate in the treatment of eclampsia and pre‐eclampsia: an overview of the evidence from randomised trials

Cardiac Drug Therapy

Contact Info

Product

Resources

About